Ocular Therapeutix, Inc. is a fully-integrated biopharmaceutical company. AXPAXLI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases and conditions of the eye.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļOCUL
āļāļ·āđāļāļāļĢāļīāļĐāļąāļOcular Therapeutix Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJul 25, 2014
āļāļĩāļāļĩāđāļDugel (Pravin U)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ274
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļJul 25
āļāļĩāđāļāļĒāļđāđ15 Crosby Drive
āđāļĄāļ·āļāļBEDFORD
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ01730
āđāļāļĢāļĻāļąāļāļāđ17813574000
āđāļ§āđāļāđāļāļāđhttps://www.ocutx.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļOCUL
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJul 25, 2014
āļāļĩāļāļĩāđāļDugel (Pravin U)
Dr. Pravin U. Dugel, M.D.
Dr. Pravin U. Dugel, M.D.
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
Dr. Richard L. Lindstrom, M.D.
Dr. Richard L. Lindstrom, M.D.
Independent Director
Dr. Namrata Saroj
Chief Business Officer
Mr. Charles M. Warden
Lead Independent Director
Lead Independent Director
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Dr. Sanjay Nayak, M.B.B.S., Ph.D.
Dr. Sanjay Nayak, M.B.B.S., Ph.D.
Chief Strategy Officer
Ms. Merilee Raines, CPA
Independent Director
Dr. Seung Suh Hong, Ph.D.
Dr. Seung Suh Hong, Ph.D.
Independent Director
Ms. Leslie J. Williams
Independent Director
Mr. Donald D. Notman, Jr.
Mr. Donald D. Notman, Jr.
Chief Operating Officer
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Dr. Pravin U. Dugel, M.D.
Dr. Pravin U. Dugel, M.D.
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
Dr. Richard L. Lindstrom, M.D.
Dr. Richard L. Lindstrom, M.D.
Independent Director
Dr. Namrata Saroj
Chief Business Officer
Mr. Charles M. Warden
Lead Independent Director
Lead Independent Director
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Dr. Sanjay Nayak, M.B.B.S., Ph.D.
Dr. Sanjay Nayak, M.B.B.S., Ph.D.
Chief Strategy Officer